TLC receives Australian and Taiwan approval to initiate phase I clinical trial of TLC19 inhalable liposomal hydroxychloroquine for COVID-19

The phase I randomised, vehicle-controlled, blinded study will evaluate safety, tolerability, & pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers. Data from this trial will serve as basis for subsequent clinical trials in patients with COVID-19.

Source:

Biospace Inc.